Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

The Role of Single-Nucleotide Polymorphisms in Pituitary Adenomas Tumorigenesis.

Shah SS, Aghi MK.

Cancers (Basel). 2019 Dec 9;11(12). pii: E1977. doi: 10.3390/cancers11121977. Review.

2.

The neurosurgery applicant's "arms race": analysis of medical student publication in the Neurosurgery Residency Match.

Wadhwa H, Shah SS, Shan J, Cheng J, Beniwal AS, Chen JS, Gill SA, Mummaneni N, McDermott MW, Berger MS, Aghi MK.

J Neurosurg. 2019 Nov 1:1-9. doi: 10.3171/2019.8.JNS191256. [Epub ahead of print]

PMID:
31675693
3.

The Phenotypes of Proliferating Glioblastoma Cells Reside on a Single Axis of Variation.

Wang L, Babikir H, Müller S, Yagnik G, Shamardani K, Catalan F, Kohanbash G, Alvarado B, Di Lullo E, Kriegstein A, Shah S, Wadhwa H, Chang SM, Phillips JJ, Aghi MK, Diaz AA.

Cancer Discov. 2019 Dec;9(12):1708-1719. doi: 10.1158/2159-8290.CD-19-0329. Epub 2019 Sep 25.

PMID:
31554641
4.

Fibronectin in malignancy: Cancer-specific alterations, protumoral effects, and therapeutic implications.

Rick JW, Chandra A, Dalle Ore C, Nguyen AT, Yagnik G, Aghi MK.

Semin Oncol. 2019 Jun;46(3):284-290. doi: 10.1053/j.seminoncol.2019.08.002. Epub 2019 Aug 27. Review.

PMID:
31488338
5.

Autophagy as a mechanism for anti-angiogenic therapy resistance.

Chandra A, Rick J, Yagnik G, Aghi MK.

Semin Cancer Biol. 2019 Aug 28. pii: S1044-579X(19)30014-8. doi: 10.1016/j.semcancer.2019.08.031. [Epub ahead of print] Review.

PMID:
31472232
6.

Introduction to Pituitary Adenomas.

Aghi MK, Blevins LS Jr.

Neurosurg Clin N Am. 2019 Oct;30(4):xiii. doi: 10.1016/j.nec.2019.07.001. No abstract available.

PMID:
31471060
7.

Molecular Biology of Pituitary Adenomas.

Faltermeier CM, Magill ST, Blevins LS Jr, Aghi MK.

Neurosurg Clin N Am. 2019 Oct;30(4):391-400. doi: 10.1016/j.nec.2019.05.001. Epub 2019 Jul 5. Review.

PMID:
31471046
8.

From bench to bedside: trends in National Institutes of Health funding for neurosurgeons from 1991 to 2015.

Jahangiri A, Flanigan PM, Arnush M, Chandra A, Rick JW, Choi S, Chou A, Berger MS, Aghi MK.

J Neurosurg. 2019 Aug 30:1-10. doi: 10.3171/2019.1.JNS181531. [Epub ahead of print]

PMID:
31470404
9.

Editorial. Chronic convection-enhanced delivery: the next frontier in regional drug infusion for glioblastoma.

Butowski NA, Bringas JR, Bankiewicz KS, Aghi MK.

J Neurosurg. 2019 Aug 2:1-3. doi: 10.3171/2019.4.JNS19614. [Epub ahead of print] No abstract available.

PMID:
31374552
10.

Systemic therapy for brain metastases.

Rick JW, Shahin M, Chandra A, Dalle Ore C, Yue JK, Nguyen A, Yagnik G, Sagar S, Arfaie S, Aghi MK.

Crit Rev Oncol Hematol. 2019 Oct;142:44-50. doi: 10.1016/j.critrevonc.2019.07.012. Epub 2019 Jul 22. Review.

11.

Correction: Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes.

Yagnik G, Rutkowski M, Shah SS, Aghi MK.

Oncotarget. 2019 Jul 2;10(42):4350. doi: 10.18632/oncotarget.27048. eCollection 2019 Jul 2. No abstract available.

12.

Insurance type impacts the economic burden and survival of patients with newly diagnosed glioblastoma.

Chandra A, Young JS, Dalle Ore C, Dayani F, Lau D, Wadhwa H, Rick JW, Nguyen AT, McDermott MW, Berger MS, Aghi MK.

J Neurosurg. 2019 Jun 21:1-11. doi: 10.3171/2019.3.JNS182629. [Epub ahead of print]

PMID:
31226687
13.

Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes.

Yagnik G, Rutowski MJ, Shah SS, Aghi MK.

Oncotarget. 2019 Mar 15;10(22):2212-2223. doi: 10.18632/oncotarget.26775. eCollection 2019 Mar 15.

14.

Meningioma metastases: incidence and proposed screening paradigm.

Dalle Ore CL, Magill ST, Yen AJ, Shahin MN, Lee DS, Lucas CG, Chen WC, Viner JA, Aghi MK, Theodosopoulos PV, Raleigh DR, Villanueva-Meyer JE, McDermott MW.

J Neurosurg. 2019 Apr 5:1-9. doi: 10.3171/2019.1.JNS181771. [Epub ahead of print]

PMID:
30952122
15.

Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966.

Lee TJ, Nair M, Banasavadi-Siddegowda Y, Liu J, Nallanagulagari T, Jaime-Ramirez AC, Guo JY, Quadri H, Zhang J, Bockhorst KH, Aghi MK, Carbonell WS, Kaur B, Yoo JY.

Mol Cancer Ther. 2019 Jun;18(6):1127-1136. doi: 10.1158/1535-7163.MCT-18-0953. Epub 2019 Mar 29.

PMID:
30926634
16.

Surgical Outcomes, Complications, and Management Strategies for Foramen Magnum Meningiomas.

Magill ST, Shahin MN, Lucas CG, Yen AJ, Lee DS, Raleigh DR, Aghi MK, Theodosopoulos PV, McDermott MW.

J Neurol Surg B Skull Base. 2019 Feb;80(1):1-9. doi: 10.1055/s-0038-1654702. Epub 2018 May 28.

PMID:
30733894
17.

Immunotherapy for High Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons.

Young JS, Dayani F, Morshed RA, Okada H, Aghi MK.

World Neurosurg. 2019 Jan 21. pii: S1878-8750(19)30106-8. doi: 10.1016/j.wneu.2018.12.222. [Epub ahead of print] Review.

PMID:
30677574
18.

Surgical outcomes after reoperation for recurrent non-skull base meningiomas.

Magill ST, Dalle Ore CL, Diaz MA, Jalili DD, Raleigh DR, Aghi MK, Theodosopoulos PV, McDermott MW.

J Neurosurg. 2018 Nov 1:1-9. doi: 10.3171/2018.6.JNS18118. [Epub ahead of print]

PMID:
30544357
19.

Presence of Histopathological Treatment Effects at Resection of Recurrent Glioblastoma: Incidence and Effect on Outcome.

Dalle Ore CL, Chandra A, Rick J, Lau D, Shahin M, Nguyen AT, McDermott M, Berger MS, Aghi MK.

Neurosurgery. 2019 Dec 1;85(6):793-800. doi: 10.1093/neuros/nyy501.

PMID:
30445646
20.

Growth hormone and prolactin-staining tumors causing acromegaly: a retrospective review of clinical presentations and surgical outcomes.

Rick J, Jahangiri A, Flanigan PM, Chandra A, Kunwar S, Blevins L, Aghi MK.

J Neurosurg. 2018 Sep 1:1-7. doi: 10.3171/2018.4.JNS18230. [Epub ahead of print]

PMID:
30215558
21.

Interfacility neurosurgical transfers: an analysis of nontraumatic inpatient and emergency department transfers with implications for improvements in care.

Safaee MM, Morshed RA, Spatz J, Sankaran S, Berger MS, Aghi MK.

J Neurosurg. 2018 Jul 1:1-9. doi: 10.3171/2018.3.JNS173224. [Epub ahead of print]

PMID:
30074453
22.

Medical versus surgical treatment of prolactinomas: an analysis of treatment outcomes.

Rutkowski MJ, Aghi MK.

Expert Rev Endocrinol Metab. 2018 Jan;13(1):25-33. doi: 10.1080/17446651.2018.1411798. Epub 2017 Dec 7. Review.

PMID:
30063440
23.

Functional brain mapping: overview of techniques and their application to neurosurgery.

Sagar S, Rick J, Chandra A, Yagnik G, Aghi MK.

Neurosurg Rev. 2019 Sep;42(3):639-647. doi: 10.1007/s10143-018-1007-4. Epub 2018 Jul 13. Review.

PMID:
30006663
24.

Disparities in health care determine prognosis in newly diagnosed glioblastoma.

Chandra A, Rick JW, Dalle Ore C, Lau D, Nguyen AT, Carrera D, Bonte A, Molinaro AM, Theodosopoulos PV, McDermott MW, Berger MS, Aghi MK.

Neurosurg Focus. 2018 Jun;44(6):E16. doi: 10.3171/2018.3.FOCUS1852.

25.

Safety and outcomes of resection of butterfly glioblastoma.

Dayani F, Young JS, Bonte A, Chang EF, Theodosopoulos P, McDermott MW, Berger MS, Aghi MK.

Neurosurg Focus. 2018 Jun;44(6):E4. doi: 10.3171/2018.3.FOCUS1857.

PMID:
29852771
26.

Surgical outcomes after reoperation for recurrent skull base meningiomas.

Magill ST, Lee DS, Yen AJ, Lucas CG, Raleigh DR, Aghi MK, Theodosopoulos PV, McDermott MW.

J Neurosurg. 2018 May 4;130(3):876-883. doi: 10.3171/2017.11.JNS172278.

PMID:
29726777
27.

Initial Experience with Intraoperative Phosphorous-32 Brachytherapy During Resection of Malignant Spinal Tumors.

Dalle Ore CL, Ames CP, Magill ST, Deviren V, Aghi MK, Lau D.

World Neurosurg. 2018 Jul;115:e785-e793. doi: 10.1016/j.wneu.2018.04.105. Epub 2018 Apr 24.

PMID:
29702311
28.

A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment.

Griveau A, Seano G, Shelton SJ, Kupp R, Jahangiri A, Obernier K, Krishnan S, Lindberg OR, Yuen TJ, Tien AC, Sabo JK, Wang N, Chen I, Kloepper J, Larrouquere L, Ghosh M, Tirosh I, Huillard E, Alvarez-Buylla A, Oldham MC, Persson AI, Weiss WA, Batchelor TT, Stemmer-Rachamimov A, Suvà ML, Phillips JJ, Aghi MK, Mehta S, Jain RK, Rowitch DH.

Cancer Cell. 2018 May 14;33(5):874-889.e7. doi: 10.1016/j.ccell.2018.03.020. Epub 2018 Apr 19.

29.

Petrous Face Meningiomas: Classification, Clinical Syndromes, and Surgical Outcomes.

Magill ST, Rick JW, Chen WC, Haase DA, Raleigh DR, Aghi MK, Theodosopoulos PV, McDermott MW.

World Neurosurg. 2018 Jun;114:e1266-e1274. doi: 10.1016/j.wneu.2018.03.194. Epub 2018 Apr 4.

30.

Histopathological features predictive of local control of atypical meningioma after surgery and adjuvant radiotherapy.

Chen WC, Magill ST, Wu A, Vasudevan HN, Morin O, Aghi MK, Theodosopoulos PV, Perry A, McDermott MW, Sneed PK, Braunstein SE, Raleigh DR.

J Neurosurg. 2018 Apr 6;130(2):443-450. doi: 10.3171/2017.9.JNS171609.

PMID:
29624151
31.

Relationship between tumor location, size, and WHO grade in meningioma.

Magill ST, Young JS, Chae R, Aghi MK, Theodosopoulos PV, McDermott MW.

Neurosurg Focus. 2018 Apr;44(4):E4. doi: 10.3171/2018.1.FOCUS17752.

PMID:
29606048
32.

Tuberculum sellae meningiomas: grading scale to assess surgical outcomes using the transcranial versus transsphenoidal approach.

Magill ST, Morshed RA, Lucas CG, Aghi MK, Theodosopoulos PV, Berger MS, de Divitiis O, Solari D, Cappabianca P, Cavallo LM, McDermott MW.

Neurosurg Focus. 2018 Apr;44(4):E9. doi: 10.3171/2018.1.FOCUS17753.

PMID:
29606045
33.

Salvage therapy outcomes for atypical meningioma.

Chen WC, Hara J, Magill ST, Wu A, Aghi MK, Theodosopoulos PV, Perry A, McDermott MW, Sneed PK, Raleigh DR, Braunstein SE.

J Neurooncol. 2018 Jun;138(2):425-433. doi: 10.1007/s11060-018-2813-9. Epub 2018 Feb 26.

PMID:
29480505
34.

Postoperative Delirium in Glioblastoma Patients: Risk Factors and Prognostic Implications.

Flanigan PM, Jahangiri A, Weinstein D, Dayani F, Chandra A, Kanungo I, Choi S, Sankaran S, Molinaro AM, McDermott MW, Berger MS, Aghi MK.

Neurosurgery. 2018 Dec 1;83(6):1161-1172. doi: 10.1093/neuros/nyx606.

PMID:
29462362
35.

Tumor treating fields: a new approach to glioblastoma therapy.

Rick J, Chandra A, Aghi MK.

J Neurooncol. 2018 May;137(3):447-453. doi: 10.1007/s11060-018-2768-x. Epub 2018 Jan 18. Review.

PMID:
29349613
36.

A cross-sectional study of neurosurgical department chairs in the United States.

Flanigan PM, Jahangiri A, Golubovsky JL, Karnuta JM, May FJ, Berger MS, Aghi MK.

J Neurosurg. 2018 Nov 1;129(5):1342-1348. doi: 10.3171/2017.7.JNS17567.

PMID:
29303441
37.

Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas.

Hayes J, Yu Y, Jalbert LE, Mazor T, Jones LE, Wood MD, Walsh KM, Bengtsson H, Hong C, Oberndorfer S, Roetzer T, Smirnov IV, Clarke JL, Aghi MK, Chang SM, Nelson SJ, Woehrer A, Phillips JJ, Solomon DA, Costello JF.

Neuro Oncol. 2018 Apr 9;20(5):632-641. doi: 10.1093/neuonc/nox205.

38.

Cross-activating c-Met/β1 integrin complex drives metastasis and invasive resistance in cancer.

Jahangiri A, Nguyen A, Chandra A, Sidorov MK, Yagnik G, Rick J, Han SW, Chen W, Flanigan PM, Schneidman-Duhovny D, Mascharak S, De Lay M, Imber B, Park CC, Matsumoto K, Lu K, Bergers G, Sali A, Weiss WA, Aghi MK.

Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):E8685-E8694. doi: 10.1073/pnas.1701821114. Epub 2017 Sep 26.

39.

Surgical intervention for pituitary apoplexy: an analysis of functional outcomes.

Rutkowski MJ, Kunwar S, Blevins L, Aghi MK.

J Neurosurg. 2018 Aug;129(2):417-424. doi: 10.3171/2017.2.JNS1784. Epub 2017 Sep 15.

PMID:
28946177
40.

Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history.

Chan AK, Han SJ, Choy W, Beleford D, Aghi MK, Berger MS, Shieh JT, Bollen AW, Perry A, Phillips JJ, Butowski N, Solomon DA.

Clin Neuropathol. 2017 Sep/Oct;36(5):213-221. doi: 10.5414/NP301022.

41.

Management of Chordoma and Chondrosarcoma with Fractionated Stereotactic Radiotherapy.

Vasudevan HN, Raleigh DR, Johnson J, Garsa AA, Theodosopoulos PV, Aghi MK, Ames C, McDermott MW, Barani IJ, Braunstein SE.

Front Surg. 2017 Jun 23;4:35. doi: 10.3389/fsurg.2017.00035. eCollection 2017.

42.

Atypical pituitary adenoma: a clinicopathologic case series.

Rutkowski MJ, Alward RM, Chen R, Wagner J, Jahangiri A, Southwell DG, Kunwar S, Blevins L, Lee H, Aghi MK.

J Neurosurg. 2018 Apr;128(4):1058-1065. doi: 10.3171/2016.12.JNS162126. Epub 2017 Jun 9.

PMID:
28598278
43.

Improved Survival with Decreased Wait Time to Surgery in Glioblastoma Patients Presenting with Seizure.

Flanigan PM, Jahangiri A, Kuang R, Truong A, Choi S, Chou A, Rick JW, Chang SM, Molinaro AM, McDermott MW, Berger MS, Aghi MK.

Neurosurgery. 2017 Nov 1;81(5):824-833. doi: 10.1093/neuros/nyx084.

44.

Developing an Algorithm for Optimizing Care of Elderly Patients With Glioblastoma.

Flanigan PM, Jahangiri A, Kuang R, Truong A, Choi S, Chou A, Molinaro AM, McDermott MW, Berger MS, Aghi MK.

Neurosurgery. 2018 Jan 1;82(1):64-75. doi: 10.1093/neuros/nyx148.

PMID:
28475720
45.

In Reply: Factors Predicting Recurrence After Resection of Clival Chordoma Using Variable Surgical Approaches and Radiation Modalities.

Jahangiri A, Chin AT, Wagner JR, Kunwar S, Ames C, Chou D, Barani I, Parsa AT, McDermott MW, Benet A, El-Sayed IH, Aghi MK.

Neurosurgery. 2017 Aug 1;81(2):E32. doi: 10.1093/neuros/nyx137. No abstract available.

PMID:
28379552
46.

Cost-Effectiveness Analysis of Surgical versus Medical Treatment of Prolactinomas.

Zygourakis CC, Imber BS, Chen R, Han SJ, Blevins L, Molinaro A, Kahn JG, Aghi MK.

J Neurol Surg B Skull Base. 2017 Apr;78(2):125-131. doi: 10.1055/s-0036-1592193. Epub 2016 Sep 27.

47.

Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.

Castro BA, Flanigan P, Jahangiri A, Hoffman D, Chen W, Kuang R, De Lay M, Yagnik G, Wagner JR, Mascharak S, Sidorov M, Shrivastav S, Kohanbash G, Okada H, Aghi MK.

Oncogene. 2017 Jun 29;36(26):3749-3759. doi: 10.1038/onc.2017.1. Epub 2017 Feb 20.

48.

Role of a p53 polymorphism in the development of nonfunctional pituitary adenomas.

Yagnik G, Jahangiri A, Chen R, Wagner JR, Aghi MK.

Mol Cell Endocrinol. 2017 May 5;446:81-90. doi: 10.1016/j.mce.2017.02.017. Epub 2017 Feb 16.

49.

GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance.

Kuang R, Jahangiri A, Mascharak S, Nguyen A, Chandra A, Flanigan PM, Yagnik G, Wagner JR, De Lay M, Carrera D, Castro BA, Hayes J, Sidorov M, Garcia JLI, Eriksson P, Ronen S, Phillips J, Molinaro A, Koliwad S, Aghi MK.

JCI Insight. 2017 Jan 26;2(2):e88815. doi: 10.1172/jci.insight.88815.

50.

Erratum to: Surgical resection of fourth ventricular ependymomas: case series and technical nuances.

Winkler EA, Birk H, Safaee M, Yue JK, Burke JF, Viner JA, Pekmezci M, Perry A, Aghi MK, Berger MS, McDermott MW.

J Neurooncol. 2017 Jan;131(2):423. doi: 10.1007/s11060-016-2343-2. No abstract available.

PMID:
28039568

Supplemental Content

Support Center